Paper Details

  1. Home
  2. Paper Details

Second-line treatment of advanced non-small cell lung cancer.

Author: ArdizzoniAndrea, CiardielloFortunato, De MarinisFilippo, De PetrisLuigi, Di MaioMassimo, GridelliCesare, HannaNasser, HeymachJohn V, PerroneFrancesco, RosellRafael, ShepherdFrances A, ThatcherNick, VansteenkisteJohan

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This article provides recommendations for second- and third-line treatment options for patients with advanced non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.
Paper Details　
Original Abstract of the Article :
After failure of first-line chemotherapy for advanced non-small cell lung cancer, many patients remain candidates to receive further antitumor treatment. To guide clinical management of these patients and to suggest priorities for clinical research, an International Panel of Experts met in Naples (I...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18379366

データ提供：米国国立医学図書館（NLM）

Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

A vast and unforgiving desert stretches before us, representing the complex landscape of advanced non-small cell lung cancer. For patients who have bravely weathered the initial onslaught of chemotherapy, the path ahead is often fraught with uncertainty. This study, akin to a beacon in the desert, aims to guide clinicians through this challenging terrain, offering insights into effective second-line treatments for these patients. The researchers assembled an International Panel of Experts, convening in the vibrant city of Naples, Italy, to synthesize the available evidence and chart a course for optimal patient management.

Guiding Patients Through the Desert of Advanced Lung Cancer

The study's findings present a glimmer of hope in the desert of advanced non-small cell lung cancer. Single-agent chemotherapy, specifically with docetaxel or pemetrexed, emerges as the preferred treatment option for patients with a performance status of 0 to 2 who are eligible for second-line therapy. This approach, the authors suggest, offers a balance of efficacy and tolerability. Furthermore, the study underscores the importance of erlotinib, a targeted therapy, as a viable alternative for patients who are unable to tolerate chemotherapy. While gefitinib, another targeted therapy, failed to demonstrate superiority to placebo in second- or third-line settings, it has shown promise in selected patient groups.

A Compass for Navigating the Desert

This study offers a much-needed compass for clinicians and patients traversing the arid landscape of advanced non-small cell lung cancer. The researchers have provided a roadmap for navigating this complex disease, highlighting the most promising treatment strategies and emphasizing the importance of personalized care. Their work serves as a reminder that even in the most challenging of medical deserts, hope and effective treatments can be found.

Dr. Camel's Conclusion

This comprehensive review provides a valuable framework for guiding clinical decision-making in the treatment of advanced non-small cell lung cancer, emphasizing the need for personalized therapy tailored to individual patient characteristics and disease stage.
Date :
  1. Date Completed 2008-05-27
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

18379366

DOI: Digital Object Identifier

S1556-0864(15)31445-3

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.